Open AccessCommentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Author(s) -
Sunit Das,
Arjun Sahgal,
James Perry
Publication year - 2020
Publication title -
frontiers in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.834
H-Index - 83
ISSN - 2234-943X
DOI - 10.3389/fonc.2020.00066
Subject(s) - temozolomide , lomustine , medicine , glioblastoma , oncology , open label , o 6 methylguanine dna methyltransferase , bevacizumab , dacarbazine , progression free survival , randomized controlled trial , chemotherapy , cancer research , methylation , methyltransferase , vincristine , biology , gene , cyclophosphamide , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom